BioSpace News Archive

Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases, ARDS associated with COVID-19, and diabetic complications, will release its financial results for the second quarter ended June 30, 2020, before the market open on Wednesday, August 12, 2020, and host a webcast and conference call at 8:30am ET. Wednesday, August 12th @ 8:30amET Inves

Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the second quarter ended June 30, 2020 and provided an update of its ongoing development activities. Business Updates Patient enrollment was initiated in a randomized, double-blind, placebo-controlled Phase 3 study of AK002 in patients with eosinoph

Initiated the pivotal GEM-3 clinical study evaluating B-VEC in DEB patients Today announced enrollment of 1 st patient in Phase 2 clinical study evaluating KB105 in ARCI patients On track to initiate Phase 1 trial of KB301 for an aesthetic indication in 2H 2020 Strong balance sheet with June 30, 2020 cash, cash equivalents and marketable securities of $297 million

Presented positive topline data from the pivotal Phase 3 REST-ON study Announced today that results of the data analyses for the secondary endpoints of the REST-ON study were consistent with the primary analyses and further demonstrated the overall statistical significance of FT218 compared to placebo Completed the pre-NDA meeting for FT218 with the Food and Drug Administration First patient dosed in the open-label extension/switch study of investigational once-nightly FT218

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immune-oncology indications, today reported top-line data from a week 8 interim analysis of the Company’s ongoing ECLIPSE Phase 2 clinical trial of etokimab,

Project Originally Funded at George Washington University by COVID-19 Technology Maturation Grant No Saliva or Blood Needed Potential to Allow Public Health Professionals to Immediately Diagnose COVID-19 Infection Via Breath Sample and Track Through A Mobile Device

Volpara Solutions will spotlight the Volpara®Platform™, a comprehensive suite of artificial intelligence and software tools that improve breast cancer detection, at the Association for Medical Imaging Management (AHRA) 2020 virtual conference on August 11-13.

Fapon Biotech Inc. (Fapon), a global leading IVD raw materials and one-stop solutions company, announces a new COVID-19 donation to meet the urgent demand for development and optimization of reliable quality controls for high-quality antibody tests by donating 100 million Anti-SARS-CoV-2 Fully Human RBD IgM & IgG QC test materials. T

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) (“China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China , today announced that the Company plans to release its second quarter 2020 financial results on Monday, August 17, 2020 after the market closes. The Company’s management

Urges Stockholders to Sign, Date and Promptly Return the BLUE Proxy Card to Support CytRx’s Highly-Experienced Directors at the September 3rd Annual Meeting